Amgen Inc.'s legacy products saw significant declines in the first quarter in the face of generics and biosimilars, but the firm is confident newer products can eventually pick up the slack. However, sales of its new migraine therapy Aimovig (erenumab) declined from the fourth quarter.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?